scholarly journals Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Dorota Diakowska ◽  
Krystyna Markocka-Mączka ◽  
Piotr Szelachowski ◽  
Krzysztof Grabowski
Keyword(s):  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Tissue ◽  
Serum Levels ◽  
Normal Mucosa ◽  
Serum Adiponectin ◽  
Gastroesophageal Cancer ◽  
Tumor Tissues ◽  
Positive Correlations

The aim of the study was the investigation of relationship between cachexia syndrome and serum resistin, adiponectin, and apelin in patients with gastroesophageal cancer (GEC).Material and Methods. Adipocytokines concentrations were measured in sera of 85 GEC patients and 60 healthy controls. They were also evaluated in tumor tissue and appropriate normal mucosa of 38 operated cancer patients.Results. Resistin and apelin concentrations were significantly higher in GEC patients than in the controls. The highest resistin levels were found in cachectic patients and in patients with distant metastasis. Serum adiponectin significantly decreased in GEC patients with regional and distant metastasis. Serum apelin was significantly higher in cachectic patients than in the controls. Apelin was positively correlated with hsCRP level. Resistin and apelin levels increased significantly in tumor tissues. Weak positive correlations between adipocytokines levels in serum and in tumor tissue were observed.Conclusions. Resistin is associated with cachexia and metastasis processes of GEC. Reduction of serum adiponectin reflects adipose tissue wasting in relation to GEC progression. Correlation of apelin with hsCRP can reflect a presumable role of apelin in systemic inflammatory response in esophageal and gastric cancer.

The correlation among tissue, serum adiponectin levels and histopathological variables in gastric cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22199-e22199
Author(s):  
A. Bilici ◽  
D. O. Guler ◽  
M. Seker ◽  
B. O. Ustaalioglu ◽  
B. Sonmez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Perineural Invasion ◽  
Tumor Tissue ◽  
Inverse Correlation ◽  
Serum Levels ◽  
Serum Adiponectin ◽  
Tissue Levels ◽  
Gastric Cancer Patients ◽  
Demographic Features

e22199 Background: Adiponectin is a new peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity in different cell types.The previous studies showed that the serum levels of adiponectin are decreased in patients with endometrial and breast cancer.In our study, demographic features and histopathological variables and the relationship among adiponectin levels of serum and gastric tissue were analyzed in gastric cancer patients. Methods: Thirty-five consecutive patients with gastric cancer included in this study.The serum levels of glucose, insulin, c-peptide, HbA1c, lipids and adiponectin were measured in patients.In addition, normal and tumor tissue levels of adiponectin were also detected.We analyzed the correlation among these parameters and patients demographic features, such as age, gender, body mass index (BMI) and histopathological variables. Results: Patients characteristics included 24 males (68.5%), 11 females (31.5%); median age was 64 (range:41–85). The mean serum, normal and tumor tissue levels of adiponectin were 49.4±0.8, 48.2±4.2, 48.6±2.9 ng/ml, respectively. There was no relationship among serum, normal and tumor tissue adiponectin levels (p>0.05).There was inverse correlation between the normal tissue levels of adiponectin and insulin (p=0.002).The serum adiponectin levels were significantly associated with tumor localization (p=0.03).However, there was inverse correlation between serum adiponectin levels and perineural invasion (p=0.02).In subgroup analysis, the serum, normal and tumor tissue levels of adiponectin in woman were not different compared with those in male patients (p>0.05).No relations were detected among tumor stage, grade, nodal status, lymphatic and vascular invasion, the other insulin-resistant status parameters and the levels of serum, normal and tumor tissue adiponectin (p>0.05). Conclusions: Our results suggest that no correlations among the levels of serum adiponectin,normal tissue and tumor tissue adiponectin levels,patients demographic features and histopathological variables except for the association of serum adiponectin with tumor localization and perineural invasion detected in gastric cancer patients. No significant financial relationships to disclose.

High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients

2014 ◽  
Vol 29 (1) ◽  
pp. e30-e39 ◽  
Author(s):  
Ariel Zwenger ◽  
Martin Rabassa ◽  
Sandra Demichelis ◽  
Gabriel Grossman ◽  
Amada Segal-Eiras ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Normal Mucosa ◽  
Poor Survival ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Colorectal Cancer Patients

Aim Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features. Methods Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented. Twenty-six adenoma and 68 histological normal mucosa specimens were analyzed. An immunohistochemical approach was applied and statistical analysis was performed. Results In tumor samples, MUC1, sLea, and sLex were highly expressed (94%, 67%, and 91%, respectively); also, we found a significantly increased expression of the 3 antigens in primary tumors and metastatic lymph nodes compared with normal mucosa and adenomas. MUC2 was expressed in 52% of both normal mucosa and CRC samples; this reactivity significantly decreased in metastatic lymph nodes (p<0.05). A multiple comparison analysis showed that MUC1 and sLex discriminated among 3 groups: normal, adenoma, and CRC tissues. The increase of sLex expression showed an association with recurrence, and survival analysis showed that a high sLex staining was significantly associated with a poor survival. By multivariate analysis MUC1 inmunoreactivity correlated positively and significantly with tumor size, while MUC2 expression showed the opposite correlation. Conclusions The correlation of sLex overexpression in primary tumors and metastatic lymph nodes, the discrimination among the normal, adenoma, and CRC groups based on sLex expression, as well as its association with recurrence and survival, all suggest a prognostic role of sLex in Argentinian CRC patients.

scholarly journals Role of Regulatory B Cells in the Progression of Cervical Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Zhifang Chen ◽  
Yuejie Zhu ◽  
Rong Du ◽  
Nannan Pang ◽  
Fengbo Zhang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Intraepithelial Neoplasia ◽  
Serum Levels ◽  
Hpv Infection ◽  
Control Group ◽  
Cell Percentage

This study is to investigate the role of regulatory B (Breg) cells in cervical cancer. In total, 70 cases of cervical cancer, 52 cases of cervical intraepithelial neoplasia (CIN), and 40 normal controls were enrolled. The percentage of Breg cells was detected by flow cytometry. Serum levels of IL-10 were measured by ELISA. The correlation between Breg cells and the clinical characterizations of cervical cancer was analyzed. The inhibition effect of Breg cells on CD8+ T cells was tested by blocking IL-10 in vitro. The percentage of CD19+CD5+CD1d+ Breg cells and the level of IL-10 of patients with cervical cancer or CIN were significantly higher than those in the control group (P<0.05). And the postoperative levels of Breg cells and IL-10 were significantly lower than the preoperative levels (P<0.05). Breg cells and the IL-10 level were positively correlated in cervical cancer patients (r=0.516). In addition, the Breg cell percentage was closely related to the FIGO stages, lymph node metastasis, tumor differentiation, HPV infection, and the tumor metastasis of cervical cancer (P<0.05). The Breg cell percentage was negatively correlated with CD8+ T cells of cervical cancer patients (r=‐0.669). The level of IL-10 in the culture supernatant of Bregs treated with CpG was significantly higher than that of non-Bregs (P<0.05). After coculture with Bregs, the quantity of CD8+ T cells to secrete perforin and Granzyme B was significantly decreased, and this effect was reversed after blocking IL-10 by a specific antibody. Breg cells are elevated in cervical cancer and associated with disease progression and metastasis. Moreover, they can inhibit the cytotoxicity of CD8+ T cells.

scholarly journals Spiritual Beliefs Add To the Perceived Health of Cancer Patients

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Devakinandan Sharma ◽  
Gyanesh Kumar Tiwari ◽  
Gyanesh Kumar Tiwar
Keyword(s):  
Cancer Patients ◽  
Perceived Health ◽  
Spiritual Beliefs ◽  
Future Directions ◽  
Care Givers ◽  
Correlational Research ◽  
History Of ◽  
Positive Correlations ◽  
Healthy Participants

The study aimed to examine the impacts of spiritual beliefs of diagnosed cancer patients and normal healthy participants on their perceived health. The present research employed a correlational research design to collect and analyze data. The purposive sampling method was used to select the participants in the study. Sixty diagnosed male (M = 52.32, SD = 10.52) and female (M = 51.68, SD = 6.90) cancer patients and 60 normal healthy male (M = 44.00, SD = 10.45) and female (M = 47.15, SD = 11.32) participants constituted the samples for the study. The findings of the study evinced that spiritual beliefs had important role in shaping the nature and extent of the perceived health of the cancer patients and normal healthy participants. The gender has also been observed to play pivotal role in impacting the perceived health of the participants. It was also observed that spiritual beliefs had shown positive correlations with the scores of perceived health of the male, female and all the cancer patients and normal healthy participants. An important finding of the study denoted that spiritual beliefs contributed significantly and even higher in degree to the scores of the perceived health of the participants inflicted with cancer as compared to the participants with no known history of chronic diseases. In essence, the findings of the study corroborated the important role of spiritual beliefs in determining the perceived health of the participants suffering from fatal disease like cancer. The findings of the study have significant implications in understanding the spiritual beliefs and perceived health of the patients inflicted with fatal diseases and it will benefit equally health professional, care-givers and public at large. The limitations and future directions for future researchers have been discussed at the end.

Increased Level of Soluble Interleukin-2 Receptor in Advanced Solid Tumors: A Preliminary Study

1988 ◽  
Vol 74 (6) ◽  
pp. 633-637 ◽  
Author(s):  
Franco Rovelli ◽  
Paolo Lissoni ◽  
Sergio Crispino ◽  
Sandro Barni ◽  
Gabriele Fumagalli ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Solid Tumors ◽  
Interleukin 2 ◽  
Normal Subjects ◽  
Serum Levels ◽  
High Serum ◽  
Human Solid Tumors ◽  
Soluble Interleukin 2 Receptor ◽  
Preliminary Study

Both activated normal and transformed lymphocytes produce not only cell-associated but also cell-free IL-2R. Evidence of high serum concentrations of IL-2R appears to serve as a tumor marker in patients with lymphomas On the contrary, the role of soluble IL-2R in solid neoplasms has still to be defined. This investigation was carried out to analyze soluble IL-2R production in human solid tumors. The study included 35 patients with solid tumors (12 without and 23 with metastases), 58 healthy subjects and 6 lymphoma patients. Among cancer patients, lung and breast carcinoma were the two most frequent neoplasms. In each subject or patient, serum levels of IL-2R were measured by using an enzyme immunoassay. Moreover, in 14/23 patients with metastatic solid tumors, lymphocyte subpopulations were also evaluated. Serum levels of IL-2R were significantly higher in the cancer patients than in the normal subjects. The patients with metastatic solid tumors showed significantly higher mean levels than those without metastases, and similar to those observed in the lymphoma patients. Finally, there was no correlation between serum levels of IL-2R and the T4/T8 ratio, which was reduced in 5/14 cancer patients. Further studies will be needed to establish if elevated concentrations of IL-2R in the serum can contribute to the immunoincompetence of patients with disseminated solid neoplasms.

LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 497-497 ◽  
Author(s):  
Michela Del Prete ◽  
Mario Scartozzi ◽  
Tiziana Prochilo ◽  
Luca Faloppi ◽  
Riccardo Giampieri ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Serum Levels ◽  
Roc Curve Analysis ◽  
Group A ◽  
Group B ◽  
Colorectal Cancer Patients

497 Background: Although a demonstrated clinical efficacy, a non negligible proportion of colorectal cancer patients does not seem to benefit from regorafenib and are consequently exposed to unnecessary toxicity. LDH serum levels represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis in many tumour types. In colorectal cancer LDH showed a correlation with treatment outcome for patients receiving antiangiogenetic treatment, thus suggesting a possible interaction with the activity profile of these drugs. We analyzed the role of LDH serum levels in predicting clinical outcome for pre-treated metastatic colorectal cancer patients receiving regorafenib. The final aim was to individuate a potentially reliable and easy to use marker for patients stratification. Methods: 118 colorectal cancer patients treated with regorafenib were available for our analysis. For all patients, LDH values were collected within one month before the procedure and after treatment end. LDH cutoff value was determined by ROC curve analysis, patients were then divided into two groups (A and B, below and above cut-off level respectively). Patients were also classified according to the variation in LDH serum levels pre- and post-treatment (increased patients vs. decreased patients). Results: Patients in group A and B proved homogeneous for all clinical characteristics analyzed. In group A patients median progression free survival (PFS) was 3.18 months, whereas it was 1.87 months in group B patients (p = 0.0018). Median overall survival (OS) was 6.23 months and 3.28 months in group A and B respectively (p = 0.048). Significant differences were not noted among the 2 groups for response rate. All the other clinical variables analyzed failed to show any correlation with patients outcome. Conclusions: Our observations seem to suggest a role of LDH as a marker of clinical outcome in colorectal cancer patients receiving regorafenib. We can then speculate that high LDH patients may not be optimal candidates for regorafenib. After further confirmation in larger trial, these findings may be relevant for a better patients stratification and selection.

LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 313-313
Author(s):  
Luca Faloppi ◽  
Michela Del Prete ◽  
Mario Scartozzi ◽  
Daniele Santini ◽  
Maristella Bianconi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Serum Levels ◽  
First Line ◽  
Tract Cancer ◽  
Group A ◽  
Group B ◽  
Line Chemotherapy

313 Background: Previous data suggested that LDH serum levels may be associated with tumour hypoxia and VEGFA and VEGFR-1 over-expression. LDH may then represent an indirect marker of activated tumour neo-angiogenesis and worse prognosis in many tumour types. In our analysis, we analyzed the role of LDH serum levels in predicting clinical outcome for biliary tract cancer patients treated with first-line cisplatin and gemcitabine chemotherapy, to individuate a potentially reliable and easy to use marker for patients stratification. Methods: 71 advanced biliary tract cancer patients treated with cisplatin and gemcitabine in first-line chemotherapy were available for our analysis. For all patients, LDH values were collected within one month before treatment beginning. We chose the laboratory cut-off (Upper Normal Rate, UNR) as LDH cut-off value (450 U/l) and then we divided the patients into two groups (A and B, below and above the UNR respectively). Survival distribution was estimated by the Kaplan-Meier method. Disease control rate (DCR) was assessed with chi-square test. A significant level of 0.05 was chosen to assess the statistical significance. Results: Patients in group A (46 patients) and B (25 patients) proved homogeneous for all clinical characteristics analyzed. Median progression free survival (PFS) was 3.97 months and 1.8 months respectively in group A (patients with LDH level below the UNR) and in group B (patients with LDH level above the UNR), p=0.0064 (HR=2.07, 95%CI: 1.07-3.99). Median overall survival (OS) was 9.24 months and 2.55 months in group A and B respectively, p<0.0001 (HR=2.93; 95%CI: 1.37-6.27). DCR was 65% in group A vs. 21% in group B (p=0.004). Conclusions: Our observations seem to suggest a prognostic role of LDH in biliary tract cancer patients. Our findings showing an improved PFS and DCR in patients with low LDH serum levels also suggest a possible predictive role in patients treated with a cisplatin and gemcitabine regimen as first-line chemotherapy. After further confirmation in larger trial, these results may be relevant for a better patients stratification and selection.

Correlation of miR-600 with WT1 expression and its potential clinical significance in breast cancer

2021 ◽  
Author(s):  
Fariba Pishbin ◽  
Nasrin Ziamajidi ◽  
Roghayeh Abbasalipourkabir ◽  
Rezvan Najafi ◽  
Maryam Farhadian
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Tumor Tissue ◽  
Prognostic Biomarker ◽  
Clinical Stage ◽  
Breast Cancer Patients ◽  
Protein Levels ◽  
Node Metastasis ◽  
Tumor Tissues

Aim: The study aimed to explore miR-600 and WT1 expression and its potential clinical significance in breast cancer. Materials & methods: The expression of miR-600 and WT1 in tumor and non-tumor adjacent tissues in 45 breast cancer patients as well as serum level of miR-600 in these patients and 45 healthy group were analyzed. Results: The expression level of miR-600 in tumor tissue and serum of patients was significantly lower than non-tumor adjacent tissues and serum of controls, respectively, while WT1 mRNA and protein levels were higher in tumor tissues compared with non-tumor adjacent tissues. The miR-600 expression was correlated with lymph node metastasis and clinical stage. Conclusion: The miR-600 acts as tumor suppressor and a diagnostic and prognostic biomarker in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document